Display options
Share it on

Curr Infect Dis Rep. 2001 Apr;3(2):137-142. doi: 10.1007/s11908-996-0036-2.

Current Options for the Therapy of Chronic Hepatitis B Infection.

Current infectious disease reports

Suzane Kioko Ono-Nita, Naoya Kato, Yasushi Shiratori, Masao Omata

Affiliations

  1. Department of Gastroenterology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. [email protected].

PMID: 11286654 DOI: 10.1007/s11908-996-0036-2

Abstract

Until recently the only available treatment for chronic hepatitis B was interferon-alpha. Over the past few years a new class of antiviral has become available, the reverse transcriptase inhibitors. Lamivudine is a nucleoside analogue reverse transcriptase inhibitor that was recently approved in many countries for the treatment of hepatitis B. Despite the potent action of lamivudine, the development of new antivirals and new strategies to treat hepatitis B are still the major goal. We review the latest options for therapy of chronic hepatitis B, including combination strategies that could be an approach to improving the response rate of antivirals.

References

  1. Antiviral Res. 1996 Jan;29(1):49-51 - PubMed
  2. Hepatology. 2000 Aug;32(2):394-9 - PubMed
  3. Ann Intern Med. 1993 Aug 15;119(4):312-23 - PubMed
  4. N Engl J Med. 1998 Jul 9;339(2):61-8 - PubMed
  5. Hepatology. 1999 Mar;29(3):971-5 - PubMed
  6. Hepatology. 2000 Sep;32(3):604-9 - PubMed
  7. Gut. 2000 Apr;46(4):562-8 - PubMed
  8. JAMA. 1999 Dec 22-29;282(24):2305-12 - PubMed
  9. Hepatology. 1999 Sep;30(3):770-4 - PubMed
  10. J Gastroenterol Hepatol. 1999 May;14 Suppl:S19-21 - PubMed
  11. Transplantation. 1994 Jun 27;57(12 ):1706-8 - PubMed
  12. Antimicrob Agents Chemother. 2000 Mar;44(3):551-60 - PubMed
  13. Antimicrob Agents Chemother. 1993 Mar;37(3):441-7 - PubMed
  14. Antiviral Res. 1991 Jul;16(1):101-14 - PubMed
  15. J Hepatol. 1997 May;26(5):1148-53 - PubMed
  16. Antimicrob Agents Chemother. 1998 Dec;42(12):3209-17 - PubMed
  17. J Med Virol. 2000 Jul;61(3):380-5 - PubMed
  18. N Engl J Med. 1999 Oct 21;341(17):1256-63 - PubMed
  19. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1627-31 - PubMed
  20. Gastroenterology. 1992 Jun;102(6):2091-7 - PubMed
  21. Antimicrob Agents Chemother. 1996 Feb;40(2):380-6 - PubMed
  22. Hepatology. 1997 Jul;26(1):216-25 - PubMed
  23. J Clin Invest. 1998 Sep 1;102(5):968-75 - PubMed
  24. Transplantation. 1999 Jul 27;68(2):232-6 - PubMed
  25. Int J Antimicrob Agents. 1996 Jul;7(2):119-34 - PubMed
  26. Hepatology. 2000 Jul;32(1):129-34 - PubMed
  27. J Viral Hepat. 1999 Sep;6(5):387-95 - PubMed
  28. Antimicrob Agents Chemother. 1997 Oct;41(10):2076-82 - PubMed
  29. N Engl J Med. 1990 Aug 2;323(5):295-301 - PubMed
  30. Clin Infect Dis. 1999 May;28(5):1032-5 - PubMed
  31. Hepatology. 1991 Sep;14(3):409-15 - PubMed
  32. Digestion. 1992;52(1):61-4 - PubMed
  33. J Infect Dis. 1997 Dec;176(6):1517-23 - PubMed
  34. Hepatology. 1998 Dec;28(6):1669-73 - PubMed
  35. N Engl J Med. 1998 Jul 9;339(2):114-5 - PubMed
  36. Hepatology. 2000 Aug;32(2):413-7 - PubMed
  37. Hepatology. 1998 May;27(5):1383-7 - PubMed
  38. Transplantation. 1997 May 27;63(10 ):1415-9 - PubMed
  39. Antimicrob Agents Chemother. 1997 Jul;41(7):1444-8 - PubMed
  40. Gastroenterology. 2000 Jul;119(1):172-80 - PubMed
  41. Transplantation. 1997 Jul 15;64(1):162-3 - PubMed
  42. Hepatology. 1996 Nov;24(5):991-5 - PubMed
  43. Antimicrob Agents Chemother. 1998 Feb;42(2):369-76 - PubMed
  44. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4398-402 - PubMed
  45. J Clin Invest. 1999 Jun;103(12):1635-40 - PubMed

Publication Types